论文部分内容阅读
目的:对西妥昔单抗治疗转移性大肠癌(m CRC)进行经济学评价。方法:基于社会视角,采用二次文献研究和模型研究方法,根据接受化疗的转移性大肠癌患者健康状态发展规律,构建Markov模型,对比西妥昔单抗联合氟尿嘧啶为基础的方案(C+FBC)与单独使用氟尿嘧啶为基础的方案(FBC),以成本效果比(CER)、增量成本效果比(ICER)作为评价指标,并对结果进行敏感度分析。结果:以14 d为一个模型周期,在120个模型周期内,C+FBC组转移性大肠癌患者获得的质量调整生命年(QALY)为1.821年,FBC组转移性大肠癌患者获得的质量调整生命年(QALY)为0.942年,C+FBC组费用为3 430 757.5元,FBC组费用为617 064.5元。C+FBC组成本效果比为1 883 996.4,FBC组成本效果比为655 057.9,增量成本效果比为3 201 012.5。进行敏感性分析对结果没有影响。结论:单独使用氟尿嘧啶为基础的方案对于转移性大肠癌患者更具有成本效果。
OBJECTIVE: To evaluate the economics of cetuximab in the treatment of metastatic colorectal cancer (mCRC). Methods: Based on the social perspective, we used Markov model and Markov model to evaluate the health status of patients with metastatic colorectal cancer receiving chemotherapy based on the second-order literature and model studies. The combination of cetuximab plus fluorouracil-based regimen (C + FBC ) And fluorouracil-based regimens (FBC) alone, using the cost-effectiveness ratio (CER) and the cost-benefit ratio (ICER) as the evaluation indicators and performing sensitivity analyzes on the results. RESULTS: With 14 days as model period, QALY of C + FBC patients with metastatic colorectal cancer was 1.82 years in 120 model cycles. Quality adjustment of metastatic colorectal cancer patients in FBC group was obtained The year of life (QALY) was 0.942, the cost of C + FBC was 3430757.5 yuan, and the cost of FBC was 617.064.5 yuan. The C / FBC cost-effectiveness ratio was 1 883 996.4, the FBC cost-effectiveness ratio was 655 057.9, and the incremental cost-effectiveness ratio was 3 201 012.5. Sensitivity analysis has no effect on the results. Conclusion: Fluorouracil-based regimens alone are more cost-effective for patients with metastatic colorectal cancer.